About US

Hura Imaging is a medical imaging software company focusing on AI innovations for imaging guided treatment.

OUR MISSION

Improve the safety, efficiency, and quality of the medical imaging process, in particular for imaging-guided treatment.
HuraCTP® TECHNOLOGY
First and the only FDA cleared denoising software dedicated for CT perfusion (CTP), physics-based AI algorithm with superior performance for improving image quality .
EXAMPLE
Hura CTP® improves image quality of CTP images for all CT models, validated by rigorous multi-center study.
DV.Target® TECHNOLOGY
Top FDA approved deep learning (DL) product on the market. Results of years of original research in the DL algorithm. Superior performance for time saving and contouring results.
EXAMPLE
DV.Target Full Body of OARs.
CereFlow® TECHNOLOGY
First comprehensive commercial software dedicated for arterial spin labeling (ASL) perfusion MRI.
Supported by multiple studies and publications.
EXAMPLE
CereFlow® report for multiparametric perfusion maps with auto-processing of multi-delay pCASL data.

Our PUBLICATIONS

All Publications

Our BENEFITS

Hura technologies will significantly improve the diagnostic imaging quality for patients with cardiovascular disease and stroke, dementia, cancer as well as pediatric patients.
Patients

Patients

Improve safety and reduce the use of radiation/ contrast agent

Clinicians

Clinicians

Improve diagnostic accuracy and efficiency for treatment planning

Payers

Payers

Reduce cost and improve healthcare service provision and quality

FDA & Strategic Acquires

FDA & Strategic Acquires

Increase regulatory compliance, improve function and competitiveness of equipment to drive sales

NATIONAL INSTITUTE OF HEALTH

Funded by NIH STTR/SBIR Program

  • Awarded the NIH Small Business Technology Transfer (STTR) Phase 1 grant in 2017.
  • Awarded the NIH SBIR Phase 2 grant in 2020.

Our Timeline

Our Team

Danny JJ Wang, PhD, MSCE

Founder & Chairman

Dr. Wang is a world leading expert in medical imaging with over 20 years of experience. Dr. Wang also maintains longstanding R&D collaborations with large OEMs including Philips, Siemens, Samsung and Neusoft.

Jerry Liu, MS, MBA

Co-Founder & CEO

Mr. Liu has more than 20 years of experience in international business development, marketing, investment, M&A and strategy in the healthcare industry.

Marc Korczykowski, MB, MA

Co-Founder & Chief Commercial Officer

Mr. Korczykowski served as a Senior Advisor at Brookline Capital Markets in NY and Senior Director, Clinical Operations at a publicly traded Biotech Company. He has 15 years of experience advancing clinical diagnostics and drug discovery & development efforts.

Xin J. Qiao, MD, MS

Co-Founder & Chief Compliance Officer

10 years of Experience in Medical Imaging Software R&D

Jeffry Alger, PHD

Chief Scientist

Adjunct Professor of UCLA David Geffen School of Medicine

Fabien Scalzo, PhD

Senior AI Scientist

Associate Professor of Computer Sciences, Pepperdine University

Narisu Bai, MS

Chief Technology Officer

10 years AI and Software Development

Joy Peng, MS

Senior Product Manager

8 years Medical Software Development

our ADVISORY BOARD

David S. Liebeskind, MD

Scientific Advisor and Consultant

Director of the UCLA Stroke Center
Professor of Neurology
UCLA Department of Neurology
Director, UCLA Stroke Center
Director, Neurovascular Imaging Research Core

An Liu, PhD

Medical Advisor

Clinical Professor, Department of Radiation Oncology. Clinical Professor and Director, Division of Radiation Physics, City of Hope

Hee Kwon Song, PhD

Chief Scientist

Associate Professor of Radiologic Science at University of Pennsylvania

John Detre, MD

Chief Medical Advisor

Director at Center for Functional NeuroImaging. Professor of Neurology & Radiology at University of Pennsylvania

Michael McNitt-Gray, PhD

Chief Science Advisor

Member of Science Advisory Board
Professor of Radiology; Director of Physics & Biology in Medicine Graduate Program; UCLA David Geffen School of Medicine

Brian Walsh, MS, MBA

Chief Commercial Advisor

Chief Commercial Advisor
& National Institute of Health Advisor

SIGNIFICANT INNOVATION IN CANCER CARE

Our Partners

Contact Us.

    Your Name (required)

    Your Email (required)

    Subject

    Your Message

    Give us a Call

    215.681.7332